NewAmsterdam Pharma Company N.V.
corporate_fare Company Profile
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for NAMS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for NAMS spans 8-K, SCHEDULE 13D/A, 10-Q, 144.
Recent high-impact activity:
- NewAmsterdam Q3 Revenue Jumps to $19.2M; PREVAIL Interim Result Due 1Q2027
- NewAmsterdam Pharma Posts $19.2M in Q3 Revenue
- NewAmsterdam Doses First Patient in Phase 2b SPINOZA Alzheimer's Trial
- Frazier Life Sciences Funds Buy $2.3M of NewAmsterdam Pharma Stock
- European Commission Approves Obicetrapib as First-in-Class LDL-C Therapy
Financial Snapshot
Short Interest & Short Volume
8.32 days to coverFINRA reported short interest of 12,009,626 shares in NAMS as of the October 30, 2026 settlement, a 14.9% decrease from the prior period — about 8.3 days to cover at its recent average daily volume. On November 20, 2026, 52.1% of NAMS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.